It binds to insulin which then initiates a cascading pathway of metabolic events through the action of the enzyme phosphatidylinositol-3-kinase and the activation of insulin-1 receptor substrate
Lundgren JD, Baraniuk JN, Ostrowski NL, Kaliner MA, Shelhamer JH
Poly(ADP-ribose) polymerase (PARP) inhibitors, including olaparib, rucaparib, and talazoparib, are being evaluated in phase 2/3 trials for metastatic castration-resistant prostate cancer (mCRPC)
Sikiri P, Hahm KB, Blagaic AB, et al
huabio, ET1601-12), analysis of islet-cells by Glucagon Monoclonal antibody (1:200
This blog draws from insights shared during our recent webinar on payer perspectives on GLP-1 therapies, using data from our 2025 Trends in Drug Benefit Design Report